Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:CASNumber |
1231929-97-7
|
| gptkbp:clinicalTrialPhase |
Phase 1
Phase 2 |
| gptkbp:developedBy |
gptkb:cancer
gptkb:G1_Therapeutics |
| gptkbp:hasInChIKey |
QJQJQJQJQJQJQJ-QJQJQJQJSA-N
|
| gptkbp:hasMolecularFormula |
C21H32N6O2
|
| gptkbp:hasSMILES |
C1CN(CCC1N2CCN(CC2)C3=NC4=C(N3)C=CC(=O)N4)CCO
|
| gptkbp:heldBy |
CDK4/6 inhibitor
|
| https://www.w3.org/2000/01/rdf-schema#label |
lerociclib
|
| gptkbp:IUPACName |
6-(4-{[1-(2-hydroxyethyl)piperidin-4-yl]amino}piperidin-1-yl)pyrido[2,3-d]pyrimidin-7(8H)-one
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL3545110
57379313 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
gptkb:G1T38
GB00438 |
| gptkbp:target |
gptkb:cyclin-dependent_kinase_6
gptkb:cyclin-dependent_kinase_4 |
| gptkbp:bfsParent |
gptkb:G1_Therapeutics
|
| gptkbp:bfsLayer |
7
|